-+ 0.00%
-+ 0.00%
-+ 0.00%

Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights

Barchart·08/17/2026 16:33:00
Listen to the news

– Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets –

– Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology company –

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.